痔炎膏治疗肛肠病692例

痔炎膏治疗肛肠病６９２例王冬敏广东省汕头市第二医院（汕头５１５０００）我科于１９８７年开始，以痔炎膏应用于肛肠科治疗疾病。经临床验证，对各型痔疮、肛瘘、肛裂等肛管直肠疾病具有显著消肿、止痛、止痒作用，以其疗效好、治愈率高获得好评，报告如下。１资料与方...     

二甲双胍对Ⅱ型胶原诱导类风湿性关节炎大鼠模型的抗炎及关节保护作用的研究

目的 研究二甲双胍对Ⅱ型胶原诱导类风湿性关节炎大鼠模型的抗炎及关节保护的作用。方法 4℃下,将Ⅱ型胶原溶于醋酸中,制成混合液;再与完全弗氏佐剂以1∶1相配比制成乳剂。于大鼠尾部、肛周皮肤多点皮内注射0.3 mL乳剂;实验第7天重复操作,加强诱导1次.造模成功后,于实验第7天将大鼠随机分为5组,为高剂量二甲双胍组、低剂量二甲双胍组、甲氨蝶呤组、诱导组、正常对照组,每组10只,分别给予高剂量二甲双胍（100 mg·kg^-1·d^-1）,低剂量二甲双胍（50 mg· kg^-1·d^-1）,甲氨蝶呤（2.7 mg·kg^-1·w^-1）灌胃干预治疗,诱导组和正常对照组不给予药物,每隔2d对各组大鼠进行关节炎评分及距骨宽度测量;于第28天处死取材,再进行大鼠踝关节X线片,大鼠血清中炎症因子水平及抗炎因子水平等检测。结果 连续观察大鼠后足关节炎评分及距骨宽度测量示：高剂量二甲双胍组关节炎评分及距骨宽度较诱导组显著降低（P＜0.05）,其余两用药组较诱导组也有一定降低关节炎评分及距骨宽度的作用（P＜0.05）;X线片示：高剂量二甲双胍组可显著保留关节结构并使其免受侵蚀,而剂量低二甲双胍组和甲氨蝶呤组效果比高剂量二甲双胍组较弱,关节结构破坏程度较轻;ELISA结果示：高剂量二甲双胍组可显著降低大鼠血清中炎症因子TNF-α、IL-1β、IL-6水平（P＜0.05）,升高抗炎因子IL-10水平（P＜0.05）;低剂量二甲双胍组及甲氨蝶呤组大鼠血清中炎症因子TNF-α、IL-1β、IL-6水平较诱导组有所降低（P＜0.05）,抗炎因子IL-10水平也有升高（P＜0.05）。结论二甲双胍对于Ⅱ型胶原诱导类风湿性关节炎大鼠模型有显著的抗炎及关节保护的作用。     

丁桂凝胶贴膏镇痛抗炎作用研究

目的 :观察丁桂凝胶贴膏对不同动物模型的镇痛抗炎作用,探讨其镇痛抗炎的作用机制。方法 :将84只4~5周龄,体重18~22 g的雄性KM小鼠随机分为7组:空白组、模型组、基质对照组、扶他林软膏组、丁桂凝胶贴膏高剂量组、丁桂凝胶贴膏等效剂量组和丁桂活络膏组,每组12只。除空白组与模型组外,其余各组小鼠于相应造模部位连续贴敷给药7 d,每日1次,基质对照组给予等剂量的空白基质凝胶贴膏。分别于末次给药后30、60、90、120 min测定其痛阈值。采用热板法实验予末次给药后在小鼠右后足跖部皮下注射5%甲醛溶液20μl,观察Ⅰ、Ⅱ相疼痛期内小鼠舔右后足的累计时间,并用ELISA方法测定血清中IL-1、TNF-α含量。采用耳肿胀法抗炎实验测量小鼠左右耳片重量的差值。结果:热板法实验中90 min时,丁桂凝胶贴膏等效剂量组痛阈值为(24.87±14.67)s,模型组痛阈值为(15.28±8.23)s;120 min时,高剂量组痛阈值为(26.33±15.45)s,模型组痛阈值为(15.31±5.02);丁桂凝胶贴膏两组分别与模型组比较差异均有统计学意义(P0.05)。Ⅰ相疼痛期,累积舔足时间丁桂凝胶贴膏高剂量组为(66.70±22.83)s,模型组为(101.80±33.65)s,两者比较差异有统计学意义(P0.01);Ⅱ相疼痛期的累积舔足时间模型组为(109.50±36.78)s,丁桂凝胶贴膏高剂量组为(51.30±43.60)s,等效剂量组为(64.00±47.27)s,与模型组比较差异有统计学意义(P0.05);模型组的IL-1含量为(28.70±8.24)ng/L,丁桂凝胶贴膏高剂量组为(13.33±2.20)ng/L,与模型组比较差异有统计学意义(P0.05);模型组的TNF-α含量为(93.60±23.65)ng/L,丁桂凝胶贴膏高剂量组为(63.21±10.54)ng/L,两组比较差异有统计学意义(P0.01),等效剂量组为(72.69±16.26)ng/L,与模型组比较差异有统计学意义(P0.05);模型组耳肿胀度为(5.73±0.80)mg,丁桂凝胶贴膏高剂量组为(5.42±0.68)mg,等效剂量组为(4.98±1.52)mg,两给药组与模型组比较均有消肿趋势,但无显著性差异。结论:丁桂凝胶贴膏能明显提高热板法实验中的痛阈值,能明显减少甲醛实验中的累积舔足时间,能降低二甲苯实验中的耳肿胀度,但不明显;而其对疼痛的缓解可能是通过调节血清中的IL-1及TNF-α水平来实现的。     

柴胡疏肝散对慢性胰腺炎大鼠胰腺的核因子-κB表达和肿瘤坏死因子-α mRNA水平的影响

目的:观察不同剂量的柴胡疏肝散对慢性胰腺炎大鼠胰腺的核因子-κB表达和肿瘤坏死因子-α mRNA水平的影响,探讨其抗炎和抑制胰腺纤维化的分子机制。方法:Wistar大鼠随机分为假手术组、模型组、柴胡疏肝散低剂量组和高剂量治疗组,光镜下行胰腺病理学观察及评分;应用Westernblot法检测胰腺核因子-κB蛋白表达,应用逆转录多聚酶链反应法检测胰腺肿瘤坏死因子-α mRNA水平。结果:高剂量治疗组大鼠胰腺组织炎症、纤维化程度较模型组减轻,核因子-κB蛋白表达和肿瘤坏死因子-α mRNA的表达水平均显著降低(P0.05)。结论:柴胡疏肝散能够抑制慢性胰腺炎大鼠胰腺核因子-κB表达和肿瘤坏死因子-α mRNA水平,且呈一定剂量依赖性,可能与其发挥抗炎抗纤维化作用机制有关。     

抗衰灵膏对良性前列腺增生大鼠模型的影响

目的:探讨抗衰灵膏对大鼠良性前列腺增生(BPH)模型的作用及相关机制。方法:采用雄激素诱导法复制大鼠BPH模型,将50只造模大鼠随机分为5组,即模型组,非那雄胺阳性组,抗衰灵膏高、中、低剂量组,每组10只,分别灌胃给予4.16、2.08、1.04 g/kg抗衰灵膏溶液,非那雄胺阳性组灌胃给予0.52 mg/kg非那雄胺溶液,每日给药1次,连续给药30 d,模型组灌胃给予同体积的蒸馏水;给药期间每周称量1次大鼠体重,实验结束后称量大鼠的前列腺湿重并计算前列腺指数;同时测定血清中E2和前列腺组织中双氢睾酮(DHT)、T的含量及前列腺组织中缺氧诱导因子(HIF-1α)的表达;光镜下观察大鼠前列腺组织形态学的改变。结果:大鼠BPH模型复制成功,实验结束后与模型组大鼠前列腺湿重及前列腺指数[(0.84±0.08)g,(0.28±0.03)%]比较,抗衰灵膏高、中剂量组明显降低[(0.69±0.04)g,(0.20±0.02)%;(0.71±0.07)g,(0.22±0.03)%](P0.01);抗衰灵膏高、中剂量组均可显著降低模型大鼠前列腺组织中的T[(2.44±0.47)ng/L;(2.91±0.69)ng/L]及DHT[(88.23±13.63)nmol/L;(90.52±16.44)nmol/L](P0.01)的水平,同时使血清中的E2水平升高[(1.19±0.14)nmol/L;(1.20±0.22)nmol/L](P0.01);抗衰灵膏高剂量能够显著降低BPH大鼠前列腺组织中的HIF-1α的过度表达(P0.01);同时抗衰灵膏高剂量还可缓解由雄激素所致的大鼠BPH的症状,表现为腺上皮变薄,腺腔内分泌物减少,间质减少等。结论:抗衰灵膏可能通过降低大鼠体内雄激素水平,改善紊乱的雌、雄激素比例,同时降低BPH组织中HIF-1α表达水平,从而达到治疗BPH的效果。     

祛风止痛胶囊对关节炎模型大鼠抗炎作用及机制的实验研究

目的：研究中药祛风止痛胶囊对关节炎模型大鼠的关节炎症、肿胀、结构破坏的影响,探讨其抗炎作用机制。方法：50只雄性SD大鼠随机分为5组：正常对照组,模型组,祛风止痛胶囊低、中、高剂量组,每组10只。除正常对照组外,其他4组应用Ⅱ型胶原-弗氏完全佐剂诱导大鼠关节炎,用祛风止痛胶囊连续灌胃给药2周进行治疗,测量大鼠后肢足爪体积,观察大鼠踝关节组织病理学变化,并用ELISA方法检测大鼠血清中白细胞介素（IL）10、肿瘤坏死因子（TNF）α的含量。结果：与模型组比较,祛风止痛胶囊降低了大鼠后足爪肿胀程度。大鼠踝关节组织病理学变化显示,祛风止痛胶囊减轻滑膜组织的异常增生,炎性细胞浸润呈剂量依赖性的降低;大鼠血清中促炎细胞因子TNFα的水平变化不明显,而抑制炎症的细胞因子IL10水平明显升高。结论：中药祛风止痛胶囊通过上调抑制炎症的细胞因子IL10的水平而抑制了大鼠关节炎的滑膜增生和软骨的破坏,提示祛风止痛胶囊可作为类风湿关节炎的治疗药物。     

复方苦参凝胶节育与抗炎的体内实验研究

目的:研究复方苦参凝胶体内节育及抗炎的效果。方法:①节育实验:将60只雌性SD大鼠随机分为生理盐水组,空白凝胶组,复方苦参凝胶低(0.05 g生药/g)、中(0.10 g生药/g)、高剂量(0.15 g生药/g)组以及阳性对照(4%壬苯醇醚凝胶)组,每组10只。按上述分组雌鼠阴道内给予相应药物各200μl,然后雌雄大鼠按1∶1合笼,进行交配。在交配成功后的第12天剖腹观察雌鼠孕珠数,并计算避孕率;②抗炎实验:采用小鼠耳廓双面均匀涂抹二甲苯的致炎模型,将60只昆明种小鼠随机分为6组,分组同前,计算小鼠单侧耳的肿胀度及肿胀抑制率。结果:复方苦参凝胶高剂量组能显著抑制雌鼠的孕珠数,其孕珠数为0.00±0.00,显著低于生理盐水组(11.00±2.00,P<0.05),而与阳性对照组(0.00±0.00)比较无统计学意义(P>0.05),其避孕率为100%;在小鼠耳廓二甲苯致炎模型中,高剂量组同样能显著抑制其肿胀程度,其平均肿胀程度为10.17±2.56,显著低于生理盐水组(21.32±3.17,P<0.01),而与阳性对照组比较无统计学意义(8.53±1.89,P>0.05),其肿胀抑制率为52.3%。结论:复方苦参凝胶有较好的节育及抗炎作用,值得进一步开发并应用于临床。     

益肾健骨膏对去卵巢骨质疏松大鼠骨代谢的影响

目的 探讨益肾健骨膏对去卵巢骨质疏松大鼠骨代谢的影响及可能机制。方法 50只雌性SD大鼠被随机分为假手术组、模型组、高剂量膏方组、低剂量膏方组、阳性药物组,每组10只。假手术组、模型组给予10 mL /（kg·d）生理盐水灌胃,低、高剂量膏方组分别给予2 g /（kg·d）、13 g/（kg·d）益肾健骨膏灌胃,阳性药物组灌服6.25 mg/（kg·w）阿仑膦酸钠维D3。治疗12周后检测大鼠腰椎骨密度和腰椎最大压缩载荷,通过Elisa检测血清骨代谢指标抗酒石酸酸性磷酸酶（TRACP）、骨保护素(OPG)、Ⅰ型前胶原氨基端原肽(PINP)、Ⅰ型胶原交联羧基端肽(CTX-Ⅰ),RT-PCR检测腰椎骨组织OPG、RANKL、RANK、TRAF6的 mRNA表达,RT-PCR及Western blot检测腰椎Notch1、Notch2、Jagged1、Jagged2的基因及蛋白表达。结果 益肾健骨膏治疗12周后,与模型组比较,高剂量膏方组大鼠腰椎骨密度、最大压缩载荷,血清PINP、OPG水平,骨组织Notch1、Notch2、Jagged1、Jagged2的mRNA和蛋白表达,OPG的mRNA表达显著升高（P<0.05）,而血清TRACP、CTX-Ⅰ水平,骨组织RANKL、RANK、TRAF6的mRNA表达显著降低（P<0.05）。结论 高剂量益肾健骨膏能改善去卵巢骨质疏松大鼠骨密度、骨强度及骨代谢,其作用机制可能与Notch通路及OPG/RANKL/RANK系统有关。     

止痛消肿膏治疗闭合性软组织损伤体会

目的用自制“止痛消肿膏”治疗闭合性软组织损伤。方法骨折或关节脱位，先行手法复位后局部用止痛消肿膏外敷。结果治疗病例5000例，优3880例，有效率96％。结论该方剂药物组成合理、简单，达到活血化淤，理气止痛，消肿的作用，疗效肯定。     

消肿膏抗炎镇痛药效学研究

消肿膏是天津医院骨伤科常用的一种医院制剂，由当归、大黄、红花、乳香、没药等十余味中药组成，用于跌打损伤，腰腿疼痛。为评价消肿膏的药效，进行了抗炎镇痛动物实验，现报告如下。     

Analgesic effect of percutaneously absorbed non-steroidal anti-inflammatory drugs: an experimental study in a rat acute inflammation model

Background  

External medication that is absorbed percutaneously may be used to reduce inflammation and relieve pain from acute injuries such as ankle sprains and bruises. The plaster method of percutaneous absorption for non-steroidal anti-inflammatory drugs (NSAIDs) was established in Japan in 1988. However, due to the possibility of a placebo effect, the efficacy of this method remains unclear. This experimental study was conducted to control for the placebo effect and to study the efficacy of the plaster method in relieving pain by using a rat model of inflammation.     

理筋手法联合传统膏药治疗踝关节扭伤

目的:探讨理筋手法联合传统膏药治疗踝关节扭伤的疗效。方法:选取踝关节扭伤患者128例,依据随机数字表法分为理膏组和膏药组各64例,膏药组给予传统膏药治疗,理膏组在此基础上给予理筋手法治疗,比较两组疼痛(VAS评分)、肿胀、美国矫形外科足踝协会足功能评分(AOFAS)、治疗疗效、不良反应。结果:治疗7 d、14 d后,理膏组VAS评分分别为(1.65±0.18)分、(1.05±0.12)分,肿胀评分分别为(1.06±0.12)分、(0.62±0.08)分,膏药组VAS评分分别为(2.18±0.26)分、(1.58±0.17)分,肿胀评分分别为(1.32±0.15)分、(0.96±0.11)分,两组治疗后评分明显低于治疗前,且理膏组明显低于膏药组(P0.01);治疗7 d、14 d后,理膏组AOFAS得分分别为(75.12±7.68)分、(92.34±9.66)分,膏药组AOFAS得分分别为(68.47±7.12)分、(80.76±8.45)分,两组治疗后得分明显高于治疗前,且理膏组明显高于膏药组(P0.001);理膏组有效率为97%,明显高于膏药组的84%(P0.05);两组治疗期间均无不良反应发生。结论:理筋手法联合传统膏药治疗踝关节扭伤,可有效改善患者疼痛、肿胀和足功能,有利于提高疗效,且具有良好的安全性。     

颈椎通治疗颈椎病机理的实验研究

本文采用具有活血化瘀作用之颈椎通胶囊进行大鼠血液流变学（A），兔离体主动脉（B），兔颈内动脉（C），犬椎动脉（D），大鼠肠系膜活体微循环（E）实验。结果表明：颈椎通胶囊具有降低大鼠血液粘度，直接舒张兔离体血管，显著增加兔颈内动脉与犬椎动脉血流量，明显改善大鼠肠系膜微循环等作用。其中颈椎通对B、C、D的作用优于颈复康，对E的作用与复方丹参相似。     

Modulation of the inflammatory response in the rat TMJ with increasing doses of complete Freund's adjuvant

OBJECTIVES: Acute inflammation stresses the physiological system, which must respond in order to reestablish homeostasis. The purpose of this study was to determine whether bilateral temporomandibular joint (TMJ) injections of different doses of Complete Freund's Adjuvant (CFA) produced dose-dependent changes in biologic markers of acute inflammation. The ability to establish an animal model with varying degrees of joint inflammation would allow evaluation of agents or conditions that could modulate the severity of the disease. DESIGN: The TMJs of three groups of male Sprague-Dawley rats were injected with CFA containing varying doses of Mycobacterium tuberculosis (MT). A group of non-injected and a group of saline injected rats were used as controls. Food intake, body weights, swelling and chromodacryorrhea were recorded daily. Interleukin-1 beta (IL-1 beta) and corticosterone levels were assayed and condylar cartilage thickness was measured 48 h after injections. RESULTS: Twenty-four hours post-injection, bilateral TMJ swelling and chromodacryorrhea were significantly (P< 0.05) increased following 10 microg of MT and further increased with elevated MT dose. In the CFA groups food intake was attenuated (P< 0.01) 24 and 48 h post-injection and negatively correlated with dose at 24 h. Body weight was also negatively correlated with dose. TMJ retrodiscal tissues IL-1 beta was increased (P< 0.05) in a dose-dependent manner. CFA increased corticosterone (P< 0.05), but this elevation was not dose dependent. Condylar cartilage thickness was decreased in a dose-dependent manner. CONCLUSIONS: These data suggest that an intermediate dose of CFA can be used to effect submaximal levels of TMJ inflammation that will allow experimental modulation in future studies.     

A New fluorometric assay for determination of osteoblastic proliferation: Effects of glucocorticoids and insulin-like growth factor-I

A novel fluorometric proliferation assay, AlamarBlue (AB), was used to study the proliferative capacity of isolated human osteoblasts (hOBs). AB is an oxidation-reduction indicator that yields a fluorescent signal in response to metabolic activity. The assay was performed by replacing the experiment media in a microtiter plate with a 10% AB solution and measuring fluorescence after a 3–8-hour incubation. The assay was optimized with respect to incubation time, cell density, and AB concentration. When the results of the AB assay were compared with cell counting in a Bürker chamber there were consistently good correlations (r > 0.9), regardless of the agonist with which the cells were treated. The mean intraassay coefficient of variance (CV) values were 9.9–11.8% in experiments where osteoblasts were treated for 12 days with insulin-like growth factor-I (IGF-I; 100 nM), or dexamethasone (1 μM). IGF-I dose dependently, at and above 1 nM, stimulated proliferation of hOBs. This effect was detectable after 3 days and reached 130–140% of untreated controls after 12 days in culture. The effects of dexamethasone (DEX) on the proliferation rate of hOBs were more complex. In short-term cultures, 3 days, DEX dose dependently stimulated proliferation. However, at and above 6 days, DEX exerted a biphasic effect, with stimulation seen at 1–10 nM and a marked inhibition of cell proliferation at and above 100 nM. dexamethasone, hydrocortisone, prednisolone, and deflazacort had almost identical biphasic effects on osteoblastic proliferation in 12 day cultures with a stimulation seen at 1–10 nM, and a marked inhibition down to 50–60% of untreated controls at and above 100 nM. When IGF-I (0.1–100 nM; 12 day culture) was combined with different doses of DEX, IGF-I still dose dependently stimulated the proliferation rate in hOBs regardless of the amount of DEX added. The stimulatory effect of DEX (10 nM, 12 days culture) was additive to the effect of 100 nM IGF-I. We conclude that AB is an easy and reliable assay for osteoblastic cell proliferation, well suited for large scale studies of cell growth using small amounts of cells, and that IGF-I partly reverses the glucocorticoid-induced inhibition of osteoblastic proliferation. Received: 12 March 1996 / Accepted: 17 June 1996     

Mechanical assessment of polyurethane impregnated fibreglass bandages for splinting

The introduction of polyurethane (PU) resin impregnated fibreglass bandages is likely to have a significant effect on modern orthopaedic practice. The manufacturers of these products claim many improved properties compared to plaster of Paris bandages, such as , high strength to weight ratio, rapid setting time and high radiolucency. This paper reports on a series of mechanical tests designed to assess the strength, flexibility, working time and wear properties of the current range of fibreglass bandages and to compare them with plaster of Paris bandages. The results have clearly demonstrated that the fibreglass bandages are mechanically superior and offer numerous advantages over plaster of Paris for use as the definitive casting material for both weight-bearing and non-weight-bearing casts.     

Antithrombin III treatment improves parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection

BACKGROUND: Antithrombin III (AT-III) is an antithrombotic agent with known anti-inflammatory properties that is also known to attenuate acute inflammation, prevent ischemia-reperfusion injury, and disseminated intravascular coagulation (DIC) associated with sepsis and endotoxemia. Here, we examined the ability of AT-III to modify parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection (AR). METHODS: After left single lung transplantations (BN-->Lew), recipient animals were treated i.v. with 50 U/kg of human AT-III (low dose group), 500 U/kg of human AT-III (high dose group), or normal saline (control group) on days 2 and 4 posttransplant. All animals were sacrificed on day 6, and several pathological categories of acute inflammation related to AR were scored (0-4). The effect of AT-III on concanavalin A (Con A)-stimulated rat spleen cell proliferation was also examined. RESULTS: The stage of AR, and the degrees of edema, hemorrhage, and necrosis were significantly reduced in the high dose group compared with the control group. AT-III significantly inhibited rat spleen cell proliferation in response to Con A, in a dose-dependent manner. Maximal inhibition was seen at 15 U/ml in culture. Identical inhibition of Con-A-stimulated cultures occurred in both serum free and serum-containing media, indicating that AT-III inhibition of Con-A-stimulated rat spleen cell proliferation is independent of its actions on thrombin. CONCLUSIONS: 1) AT-III treatment significantly improves parameters of acute inflammation seen in a highly histoincompatible model of rat lung AR. 2) AT-III inhibits in vitro T cell proliferation to the potent mitogen Con A, suggesting that protease inhibition may inhibit T cell activation in vitro. 3). The beneficial effects of AT-III on parameters of lung AR relate to the anti-coagulant, anti-inflammatory, and possibly immunoregulatory actions of AT-III.     

Tapering immunosuppressive therapy significantly improves in vivo cutaneous delayed type hypersensitivity responses

Immunosuppressive therapy affects cell-mediated immunity and thereby increases the frequency of infections and malignancies in transplanted patients. We questioned whether reducing the immunosuppressive dose in stable kidney transplant patients has an in vivo effect on cutaneous delayed type hypersensitivity responses (DTH) reflecting cell-mediated immunity. We measured DTH responses to recall antigens (Tetanus, Diphteria, Streptococcus, Tuberculin, Candida, Trychophyton, Proteus, glycerin control) on the volar surface of the forearm in patients before and after successful reduction (50%) of the dose of mycophenolate mofetil (MMF) or azathioprine (AZA). In addition, we tested healthy individuals who were age- and sex-matched to the patient group. Results of the skin reaction test were calculated as the sum in millimeters (mm) of all positive reactions (score), and as the number of positive antigens. Patients treated with a high dose of MMF or AZA had a significantly lower test score compared to healthy controls (p=0.01). Also the number of positive antigens was reduced in patients compared to healthy controls (p=0.02). After reduction of the MMF or AZA dose, the test score and the number of positive antigens increased significantly (p=0.02, p=0.01, respectively) to comparable scores of healthy controls. Additionally, the mycophenolic acid (MPA) trough level was negatively correlated with the test score (p=0.006) and number of positive antigens (p=0.004). In conclusion, successful tapering of the MMF or AZA dose in kidney transplant patients more than 2 years after transplantation favorably affects the in vivo DTH response, reflecting an improvement of the general immunity, facilitating the defense against infection and malignancies.     

Hexcelite versus plaster of Paris: a controlled trial of the below-knee walking cast

Hexcelite and plaster of Paris below-knee walking casts were compared in a controlled clinical trial, involving 82 patients. Fewer bandage complications, problems and better comfort was found with Hexcelite compared to plaster of Paris (P less than 0.05). If all costs relating to materials, transportation, complications and extra visits due to these, were taken into account, plaster of Paris was found more expensive than Hexcelite. Based on the above an increased use of Hexcelite is recommended.     

补肾方药对去卵巢雌鼠骨质疏松症防治作用的研究

目的：为验证益肾填精方药“肾虚骨痛胶囊”防治骨质疏松症的疗效和探讨其治疗机理。方法：本文以切除卵巢雌性大鼠复制绝经后骨质疏松症模型，观察该药对去卵巢大鼠抗失骨作用。实验分为模型组、肾虚骨痛胶囊大、小剂量组、骨疏康阳性对照组和正常对照组。术后１周开始给药，持续１２０天。结果：肾虚骨痛胶囊大剂量组，与模型组比较，可以提高模鼠全身及股骨骨密度、股骨灰重、腰椎骨小梁体积、股骨无机元素 Ｃａ、 Ｐ、 Ｍｇ、 Ｚｎ、 Ｃｕ、 Ｍｎ含量，血清Ｅ_２含量用药后有增高之趋势，但与模型组比较无统计学差异。结论：肾虚骨痛胶囊可通过体内多方位调节作用达到预防和抑制骨质疏松症的发生和发展，具有较好的应用前景。